Prostatic cancer: where do we go from here?
This paper focuses on advances in prostatic cancer that occurred during the past year. Specific areas reviewed here are screening, radical surgery, locoregional disease, the no-therapy option, androgen-ablative therapy, prognostic factors, bone-specific therapy, hormone refractory disease, and prostate cancer biology.
Scher
H
H
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000628:therapy*